Beta-Adrenergic Receptor Blockers in Hypertension: Alive and Well

Area of Science:

• Cardiology
• Pharmacology

Background:

• Beta-adrenergic receptor blockers (β-blockers) are a cornerstone in managing systemic hypertension (HTN).
• They are indicated for patients with concomitant ischemic heart disease (IHD), heart failure, obstructive cardiomyopathy, aortic dissection, or cardiac arrhythmias.
• Labetalol is specifically noted for treating hypertensive emergencies and urgencies.

Purpose of the Study:

• To review the multifaceted pharmacologic properties of β-blockers.
• To evaluate the current evidence regarding perioperative β-blocker use for cardiovascular complication reduction.
• To identify patient groups who benefit most from perioperative β-blocker therapy.

Main Methods:

• Literature review of β-blocker pharmacology and clinical trial data.
• Analysis of evidence supporting perioperative β-blocker use in various surgical contexts.
• Synthesis of current guidelines and expert recommendations.

Main Results:

• β-Blockers exhibit significant heterogeneity in properties like selectivity, intrinsic activity, and elimination routes, influencing clinical selection.
• Perioperative β-blocker use may not universally benefit patients and can potentially cause harm.
• Current evidence best supports perioperative β-blocker use in patients with known IHD undergoing vascular surgery or those already on β-blockers for existing cardiovascular conditions.

Conclusions:

• The selection of β-blockers requires careful consideration of their diverse pharmacologic profiles.
• Perioperative β-blocker administration necessitates a nuanced approach, balancing potential benefits against risks.
• Restricted perioperative β-blocker use is recommended for specific high-risk patient populations.